Drug Information

General Information
Drug ID
DR00163
Drug Name
Ranitidine
Synonyms
(E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; Noctone; Nu-Ranit; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Rani-Q; Rani-nerton; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidine (USAN/INN); Ranitidine HCL; Ranitidine [USAN:BAN:INN]; Ranitidinum; Ranitidinum [INN-Latin]; Ranitiget; Ranitin; Rantacid; Rantidine; Rantidine HCL; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ul-Pep; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantac (TN); Zantadin; Zantic
Drug Type
Small molecular drug
Indication Peptic ulcer [ICD11: DA61] Approved [1]
Therapeutic Class
Antiulcer Agents
Structure
3D MOL 2D MOL
Formula
C13H22N4O3S
Canonical SMILES
CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
InChI
InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+
InChIKey
VMXUWOKSQNHOCA-UKTHLTGXSA-N
CAS Number
CAS 66357-35-5
Pharmaceutical Properties Molecular Weight 314.41 Topological Polar Surface Area 112
Heavy Atom Count 21 Rotatable Bond Count 9
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 7
XLogP
0.3
PubChem CID
3001055
PubChem SID
10036397 , 103091649 , 103155999 , 103173566 , 104171226 , 10532147 , 11111714 , 11111715 , 11113371 , 111610678 , 117377112 , 117814891 , 118258804 , 124551883 , 124636867 , 124881290 , 124881291 , 14776753 , 26612202 , 26680173 , 26748519 , 26748520 , 26753732 , 34666962 , 46505543 , 47216723 , 47515261 , 47810695 , 48184944 , 49846707 , 49968693 , 50100822 , 50107423 , 50107424 , 50139267 , 50286426 , 53790194 , 57410138 , 615112 , 7847488 , 7980484 , 8149747 , 85209253 , 85245763 , 90341455 , 92124471 , 92307665 , 92711914 , 93166337 , 99301528
ChEBI ID
ChEBI:8776
TTD Drug ID
D0B8WN
DT(s) Transporting This Drug OAT2 Transporter Info Organic anion transporter 2 Substrate [2]
OAT3 Transporter Info Organic anion transporter 3 Substrate [2]
OCT-1 Transporter Info Organic cation transporter 1 Substrate [3]
OCT-2 Transporter Info Organic cation transporter 2 Substrate [2]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OAT3 Transporter Info Km = 234 microM Human embryonic kidney cells (HEK293)-OAT3 [5]
OCT-1 Transporter Info Km = 70 microM Oocytes-OCT1 [3]
OCT-2 Transporter Info Km = 65.2 microM Human embryonic kidney cells (HEK293)-OCT2 [2]
References
1 Ranitidine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
3 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
4 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
5 Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.